[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hospital-acquired-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hospital-acquired-pneumonia":189},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,75,104,128,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644038","predictors-and-outcomes-of-ventilated-hospital-acquired-pneumonia-100644038",false,"NCT07667582","Predictors and Outcomes of Ventilated Hospital-acquired Pneumonia","Inclusion Criteria:\n\nAll patients diagnosed with HAP in the chest department, Assiut University\n\nExclusion Criteria:\n\n1. Post operative patients\n2. Tracheostomized patients\n3. Comatosed patient since admission\n4. Suspected aspiration","ALL","18 Years","100 Years",{"count":19,"type":20},151,"ESTIMATED","OBSERVATIONAL","Hospital-acquired pneumonia (HAP) is defined as an infection of the pulmonary parenchyma that develops in patients admitted to hospital for more than 48 hours and that was not incubating at the time of admission. It represents one of the most common and serious nosocomial infections, associated with significant morbidity, prolonged hospitalisation, and increased mortality in critically ill patients.\n\nThe aetiology of HAP is primarily driven by micro-aspiration of bacteria colonising the oropharynx and upper gastrointestinal tract. Pathogen distribution is shaped by the duration of hospitalisation, prior antibiotic exposure, local epidemiology, and patient characteristics. Multidrug-resistant (MDR) organisms are particularly prevalent in patients with prolonged inpatient stay and intensive care unit (ICU) admission, as critically ill patients become rapidly colonised with nosocomial pathogens.\n\nVentilator-associated pneumonia (VAP), a subgroup of nosocomial pneumonia, occurs in patients requiring tracheal intubation and mechanical ventilation for at least 48 hours. A clinically important and increasingly recognised entity is ventilated HAP (v-HAP), defined as HAP that subsequently requires tracheal intubation and mechanical ventilation. Emerging evidence indicates that v-HAP carries the highest mortality among nosocomial pneumonia subtypes in ICU patients - exceeding VAP - while non-ventilated ICU-acquired HAP carries the lowest mortality.",[24],"Hospital Acquired Pneumonia",[26,27],"HAP","ventilated HAP","RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":32},"2026-06-01",{"date":36,"type":20},"2027-06-30",{"name":38,"class":39},"Assiut University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100526419","phase-3-acyclovir-in-ventilated-patients-with-pneumonia-and-hsv-1-in-bal-100526419","NCT06134492","Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL","Effect of Acyclovir Therapy on the Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage","HerpMV","Inclusion Criteria:\n\n1. ≥ 18 years\n2. need for invasive or non-invasive respiratory support\n3. PCR HSV-1 detection in BAL (≥ 10\\^3 copies\u002Fml)\n4. Pneumonia (community or healthcare acquired, incl. ventilator-associated pneumonia)\n5. declaration of consent by the patient or legal representative\n\nExclusion Criteria:\n\n1. History of hypersensitivity to acyclovir or valacyclovir or other components of the investigational product.\n2. Pregnancy\u002FLactation\n3. Simultaneous participation in another interventional clinical trial\n4. Decision to withhold life-sustaining therapies\n5. Use of a virostatic agent (i.v. or p. os) with activity against herpes simplex (acyclovir, valacyclovir, famciclovir\u002Fpenciclovir, brivudine, cidofovir, foscarnet) for therapeutic or prophylactic reasons at the time of randomization.\n6. Solid organ transplantation, stem cell transplantation\n7. Neutropenia (absolute neutrophil count \\\u003C1500\u002Fμl (\\\u003C1.5 × 109 \u002Fl)\n8. Previous study participation in HerpMV",{"count":50,"type":20},616,"INTERVENTIONAL",[53],"PHASE3","Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her\u002Fhis life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, for example in the case of a serious illness or stress, are the viruses reactivated. They then mainly cause cold sores, which are harmless for healthy people and usually heal without therapy. However, especially in people with a weakened immune system, HSV can also cause serious infections, such as meningitis. In almost every second mechanically ventilated patient in intensive care who has pneumonia, HSV can be detected in the respiratory tract. This is caused by reactivation of the viruses as a result of the severe underlying disease and stress during intensive care therapy. Whether treatment of the herpes viruses (e.g. with acyclovir) is necessary in this situation and helps the patients to cure has not been clarified, especially as acyclovir can also cause side effects such as a deterioration in kidney function. Currently, the physicians decide to treat the herpes viruses in about half of the patients. Several studies have shown that patients for whom the physician decided to treat the viruses survived more often. However, all of these studies looked at the course of the disease only retrospectively and thus are subject to many biases (including physician selection of who receives treatment, missing data). A definitive conclusion as to whether herpesvirus therapy can be recommended cannot be drawn without doubt from these studies. Therefore, the investigators would like to investigate in a randomized controlled trial, i.e. patients are randomly assigned to the experimental (therapy of herpesviruses) or control group (no therapy of herpesviruses), the effect of therapy with acyclovir on survival in ventilated intensive care patients with lower respiratory tract infection (pneumonia) in whom a large amount of HSV was found in the respiratory tract. The goal of the study is to provide clarity on whether therapy will help patients recover.",[56,57,58,59,60],"Pneumonia, Viral","Ventilator Associated Pneumonia","Community-acquired Pneumonia","Herpes Simplex","Hospital-acquired Pneumonia",[62,59,63,64],"Pneumonia","Mechanical Ventilation","Aciclovir","2025-11-18",{"date":67,"type":32},"2025-11-21",{"date":69,"type":32},"2024-02-20",{"date":71,"type":20},"2026-12",{"name":73,"class":39},"Jena University Hospital",28,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":40},"100495584","a-study-to-learn-about-the-study-medicine-zavicefta-after-it-is-released-into-the-markets-in-korea-100495584","NCT05733104","A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","Prospective Observational Post Marketing Surveillance Study to Observe Safety and Effectiveness of Zavicefta IV","1. Adults and paediatric patients aged 3 months and older, who have been administered at least one dose of Zavicefta for the treatment of one of the indications as follows:\n\n   * Complicated intra-abdominal infection (cIAI)\n   * Complicated urinary tract infection (cUTI), including pyelonephritis\n   * Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)\n   * Other aerobic Gram-negative organism infection with limited treatment options\n2. Adults 19 years of age or older, who have been administered at least one dose of Zavicefta for the treatment of the indication as follows:\n\n   •Bacteremia associated with or suspected to be associated with cIAI, cUTI or HAP including VAP.\n3. Patients are treated with Zavicefta for the first time\n4. Patients have signed the data privacy statement.","3 Months",{"count":84,"type":20},600,"The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen, urinary tract and pneumonia which could have come from hospitalizations.\n\nThis study was required by the Ministry of Food and Drug Safety (MFDS) of Korea's regulations.",[87,88,60],"Complicated Intra-abdominal Infection","Complicated Urinary Tract Infection",[90,91,92,93],"Ceftazidime","Avibactam","safety","efficacy","2025-09-02",{"date":96,"type":32},"2025-09-03",{"date":98,"type":32},"2024-02-19",{"date":100,"type":20},"2029-09-28",{"name":102,"class":103},"Pfizer","INDUSTRY",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":51,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100536828","phase-3-dexamethasone-for-treating-severe-hospital-acquired-pneumonia-in-critically-ill-patients-with-a-proinflammatory-phenotype-100536828","NCT06269900","Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype","Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase III, Double-blind, Placebo-controlled, Randomized Trial","HAP-DEX","Inclusion Criteria:\n\n* Hospital-acquired pneumonia (HAP) according to European guidelines (Torres et al. Eur Respir J 2017): Association of two criteria among (body temperature \\> 38°C, leukocytosis\\>12000 cells per mL, leucopenia \\\u003C4000 cells per mL and purulent pulmonary secretions), appearance of a new infiltrate or change in an existing infiltrate on chest radiography, and respiratory sample (Sputum, AET, BAL, mini-BAL or blind BAL) collected for bacteriological diagnosis (results can be pending at inclusion). The diagnosis of HAP can have been made outside of ICU. Diagnosis is done at least 48 hours after hospital admission.\n* HAP severity defined as a PaO2\u002FFiO2 ratio \\\u003C 300 under mechanical ventilation.\n* Biological systemic inflammatory response defined as CPR≥ 150 mg\u002FL (15 mg\u002FdL)\\*\n* Receiving curative antimicrobial therapy for the current episode of HAP pneumonia for less than 48 hours.\n* Informed consent from a legal representative, or emergency procedure (when possible, according to national regulation, see below). If it is not possible to obtain the patient consent prior the inclusion (comatose patients), patient consent for the study continuation will be obtained as soon as deemed possible.\n* Person insured under a health insurance scheme.\n* Female of childbearing age who agree and who are able to comply with effective contraception for the 28 first days of the study.\n\nExclusion Criteria:\n\n* Pregnant women (serum or urine test), breastfeeding women.\n* Patient under legal protection (incl. under guardianship or trusteeship).\n* Hypersensitivity to dexamethasone and hypersensitivity to all of its excipients\n* Ongoing administration of glucocorticoid at the time of randomisation, such as for COVID-19 infection requiring supplemental oxygen therapy\n* Severe septic shock (norepinephrine \\> 0.4 microg\u002Fkg\u002Fmin and serum lactate level greater than 2 mmol\u002FL) at the time of randomisation\n* Prolonged use of corticosteroids at a mean minimum dose of 0.3 mg\u002Fkg\u002Fday of prednisone equivalent for \\>3 weeks in the past 60 days\n* Uncontrolled viral (hepatitis,herpes, zona, varicella) or systemic fungal infection\n* Immunosuppression pre-existing to hospitalisation (severe lymphopenia \\\u003C 500 lymphocytes\u002Fmm3, hematologic cancer, aplasia, chemotherapy\u002Fradiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug).\n* Uncontrolled psychotic disorder (acute or chronical)\n* Patients not expected to survive for more than 48 hours.\n* Participation in another drug clinical trial :\n\n  * testing steroids or anti-graft rejection drug or chemotherapy- radiotherapy for cancer\n  * And \u002F Or testing a drug regimen with a known interaction with dexamethasone,\n  * And \u002F Or whose implementation would alter the HAP-DEX 6-month follow-up, notably the collection of the primary outcome.\n  * Situations that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study","85 Years",{"count":114,"type":20},450,[53],"Determine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an international phase III, double-blind, placebo-controlled, randomized trial.",[24],"2025-08-05",{"date":120,"type":32},"2025-08-11",{"date":122,"type":32},"2024-03-26",{"date":124,"type":20},"2026-08-15",{"name":126,"class":39},"Nantes University Hospital",26,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":51,"phases":138,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100514518","phase-4-early-impact-therapy-with-ceftazidime-avibactam-via-rapid-diagnostics-100514518","NCT05979545","EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Versus Standard of Care Antibiotics and Diagnostics in Patients With Bloodstream Infection, Hospital-acquired Pneumonia or Ventilator-associated Pneumonia Due to Pseudomonas Aeruginosa or Carbapenemase Producing Enterobacterales (RAPID)","RAPID","Inclusion Criteria:\n\n1. patient developed clinical symptoms compatible with bloodstream infection, hospital-acquired or ventilator-associated pneumonia (hospital-acquired and ventilator-associated pneumonia should fulfil US CDC NHSN criteria) AND,\n2. an appropriate specimen has been received by the participating laboratory - that is, a blood culture bottle showing Gram negative bacilli or a respiratory sample collected for clinical purposes showing Gram negative bacilli on Gram stain;\n\nExclusion Criteria:\n\n1. Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR,\n2. where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR,\n3. treatment is not with the intent to cure the infection; OR,\n4. patient is incarcerated in a correctional facility; OR,\n5. patients previously randomised in this trial within the last 60 days.",{"count":137,"type":20},1900,[139],"PHASE4","The goal of this clinical trial is to propose a seamless intervention linking rapid bacterial isolate identification and antibiotic resistance gene detection and targeted antibiotic prescription to minimise time between infection onset and appropriate treatment in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales infections. This is an investigator initiated trial.\n\nThe primary hypothesis is that these interventions will lead to improved clinical outcomes amongst patients with hospital-acquired bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to carbapenem non-susceptible Pseudomonas aeruginosa or Enterobacterales, compared to standard antibiotic susceptibility testing.\n\nPatients will be randomised to either a control or intervention arm. Patients randomised to the intervention arm will have relevant specimens analysed by rapid microbiological diagnostics and will have early availability of ceftazidime-avibactam if appropriate. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics will be available to these patients as per usual institutional practice.",[142,57,143,144,60],"Blood Stream Infections","Healthcare Associated Infection","Carbapenem-Resistant Enterobacteriaceae Infection",[146,147,148,149,150,151,152,153,154,155],"rapid diagnostics","ceftazidime-avibactam","carbapenemase producing Enterobacterales","hospital-acquired","MDR","AMR","ASP","CRE","BCID2","PN Plus","2024-03-03",{"date":158,"type":32},"2024-03-06",{"date":160,"type":32},"2023-12-12",{"date":162,"type":20},"2026-12-31",{"name":164,"class":39},"National University of Singapore",4,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100518259","chinese-hospital-acquired-pneumonia-collaboration-network-epidemiology-diagnosis-and-treatment-100518259","NCT06028217","Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment","A Prospective Study on Pathogen Investigation, Risk Factors, and Prognostic Factors Analysis of Hospital Acquired Pneumonia (HAP)","CHAPTER","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Meets the clinical diagnostic criteria for HAP in the 2018 HAP\u002FVAP guidelines. Chest X-ray or CT shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) Fever, body temperature\\>38 ℃; 2) Purulent airway secretions; 3) Peripheral blood white blood cell count \\>10 × 10\\^9\u002FL or \\\u003C4 × 10\\^9\u002FL.\n3. Having qualified evidence of responsible pathogen. On the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) Qualified lower respiratory tract secretions (neutrophil count \\>25\u002Flow magnification field, epithelial cell count \\\u003C10\u002Flow magnification field, or a ratio of the two \\>2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (PSB), bronchoalveolar lavage fluid (BALF), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) Pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) The serum IgM antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific IgG antibodies in both acute and recovery phases show a 4-fold or more change. During the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture.\n4. obtained informed consent\n\nExclusion Criteria:\n\n1. Those who cannot understand and execute the investigation plan.\n2. Active pulmonary tuberculosis;\n3. Severely immunosuppressed patients: absolute neutrophil count \\\u003C0.5× 10\\^9\u002FL, CD4\\\u003C200\u002Fml.",{"count":175,"type":20},4000,"The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.\n\nThe main purposes of this study are:\n\n1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China;\n2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network;\n3. identify the molecular epidemiology of common pathogens",[60,178],"Antibiotic Resistant Infection","NOT_YET_RECRUITING","2023-08-31",{"date":182,"type":32},"2023-09-08",{"date":184,"type":20},"2023-10-01",{"date":186,"type":20},"2027-12-31",{"name":188,"class":39},"Ruijin Hospital","Hospital-Acquired Pneumonia"]